ZTS الفئة A Zoetis Inc. Class A Common Stock
NYSE · Pharmaceuticals · عرض على SEC EDGAR ↗ إغلاق أكتوبر 2, 2026 10-K/10-Q أغسطس 6, 2026
$69,69
· % من نطاق 52 أسبوعًا
· فوق الحد الأدنى
· إلى مرتفع
$68,78أدنى 52 أسبوعًا
$148,79أعلى 52 أسبوعًا
القيمة السوقية (الربع الأخير)
$28.86B
P/E (سنوي حالي)
11.5
ربح السهم (سنوي حالي)
$6.07
الإيرادات (سنوي حالي)
$9.52B
شاراتك
نطاق 52 أسبوعًا
$69–$149
تقييم المحللين
HOLD
السعر المستهدف
$96
P/E
11.5
ROE
64.4%
هامش صافي الربح
27.5%
شريط الشارات الخاص بك فارغ — قم بتثبيت مقياس في أي مكان على هذه الصفحة.
ZTS لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$69.69
القيمة السوقية (الربع الأخير)
$28.86B
P/E (سنوي حالي)
11.5
ربح السهم (سنوي حالي)
$6.07
الإيرادات (سنوي حالي)
$9.52B
ROE (سنوي حالي)
64.4%
D/E الدين/حقوق الملكية (الربع الأخير)
2.9
نطاق 52 أسبوعًا
$69–$149
ZTS مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
نطاق
أشرطة
تتكيف دقة الشريط مع الفترة المحددة - مرر مؤشر الفأرة فوق الرسم البياني لرؤية الافتتاح/الأعلى/الأدنى/الإغلاق للشريط.
حول Zoetis Inc. Class A Common Stock نظرة عامة على الشركة من ويكيبيديا
Zoetis Inc. (/zō-EH-tis/), headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries.
In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses.
The firm is named Zoetis in allusion to the Greek-derived zoological term zoetic, meaning "pertaining to life". The company was owned by Pfizer until 2013.
History
1950s to 2000s
In the 1950s, Pfizer began research on several drugs, including oxytetracycline, which was found to be effective in livestock.
In 1952, the Pfizer Agriculture Division opened a 732-acre research and development facility in Terre Haute, Indiana, called Vigo.
In 1988, the division was renamed Pfizer Animal Health.
In 1995, Pfizer acquired Norden Laboratories from GlaxoSmithKline for $1.45 billion, expanding its animal health division into small animal care, including pets.
Secondary research and development centres were opened in Kalamazoo, Michigan, in 2003.
In April 2003, Pfizer acquired Pharmacia Corporation for $60 billion in stock. Pfizer absorbed its animal health assets, which included the legacy operations of The Upjohn Company, into Pfizer Animal Health.
In December 2006, Pfizer Animal Health acquired Embrex, which provides inoculations for poultry against various diseases, for $155 million.
In March 2008, Pfizer Animal Health acquired Catapult Genetics, a developer of livestock DNA tests and gene markers, and Bovigen, which markets DNA technology.
In April 2008, Pfizer Animal Health acquired vaccine products from Schering-Plough.
In June 2009, Pfizer Animal Health acquired Vetnex Animal Health from ICICI Bank.
In October 2009, Pfizer acquired Wyeth, including its subsidiary Fort Dodge Animal Health, which was added to Pfizer Animal Health. Some assets were sold to Boehringer Ingelheim to gain regulatory approval for the transaction.
In May 2010, Pfizer Animal Health acquired Microtek, a developer of aquaculture vaccines.
2010s-present
In January 2011, Pfizer Animal Health acquired Synbiotics, a developer of immunodiagnostic tests for companion and food production animals, for $20 million.
In February 2011, Pfizer acquired King Pharmaceuticals; its Alpharma subsidiary was integrated into Pfizer Animal Health.
In June 2012, Pfizer Animal Health was renamed Zoetis.
In February 2013, Zoetis became a public company via an initial public offering, raising $2.2 billion. Most of the money raised through the IPO was used to pay off existing Pfizer debt. In June 2013, Pfizer divested itself of its remaining shares in Zoetis.
In February 2015, the company acquired a portfolio of pet drugs from Abbott Laboratories for approximately $255 million.
In July 2015, the company acquired KL Automation, a robotics company specializing in automation technology for poultry hatchery.
In November 2015, the company announced it would acquire Pharmaq, a developer of aquaculture treatments and diseases, for $765 million.
In August 2016, the company acquired Scandinavian Micro Biodevices for $80 million.
In April 2017, Zoetis acquired Ireland-based Nexvet, a company with a biologics focused technology and product candidate pipeline.
In July 2018, the company acquired Abaxis for $1.9 billion in cash.
In June 2022, Zoetis acquired Basepaws, a privately held genetics company.
In August 2022, the company acquired Newmetrica, a Scottish company that develops digital tools designed to measure health-related quality of life.
In September 2022, Zoetis acquired Jurox, which develops 150 medicines including Alfaxan.
In August 2023, the company opened a 1.4 million square foot facility on 145 acres in Lincoln, Nebraska.
In September 2023, Zoetis acquired Petmedix, a privately held Cambridge, UK-based company, to bring the benefits of species-specific antibody therapies to pet owners.
In December 2023, Zoetis acquired adivo, a German manufacturer of antibodies for pet medicine.
In October 2024, the company sold its medicated feed additive product portfolio and certain water-soluble products to Phibro Animal Health.
In February 2025, the United States Department of Agriculture granted Zoetis conditional approval to deploy its bird flu vaccine in poultry, after a bird flu outbreak had infected nearly 70 people in the USA, resulting in one death, with most cases occurring among farm workers exposed to infected poultry or cattle. In January 2025, the USDA announced plans to replenish its bird flu vaccine stockpile for poultry, aligning with the strain affecting commercial and wild bird populations, similar to efforts following major outbreaks in 2014 and 2015.
In November 2025, the company acquired Veterinary Pathology Group.
In March 2026, the company agreed to acquired the genomics business of Neogen.
In July 2026, the company agreed to acquire VitalRADS, a veterinary teleradiology platform.
Products
Zoetis' manufacturing network, includes 28 sites in 11 countries. Each facility is designed to meet chemical and infectious agent safety regulatory requirements. Many R&D operations are co-located with manufacturing sites, a collaboration that allows bringing new products to market faster.
Zoetis products include:
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
قطاعHealthcare
صناعةPharmaceuticals
موظفون14500
بلدUS
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات$9.47B2016-12-31 → 2025-12-31
ربح السهم$6.022016-12-31 → 2025-12-31
التدفق النقدي الحر$2.28B2016-12-31 → 2025-12-31
هامش صافي27.5%2016-12-31 → 2025-12-31
التقييم والنسب
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
| المقياس | اتجاه 5 سنوات | ZTS | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| P/E (سنوي حالي) | 11.5متوسط 5 سنوات ≈35.9 | ≈35.9 | 31.0 | مقوّم بأقل من قيمته | |
| السعر/المبيعات (سنوي حالي) | 3.0متوسط 5 سنوات ≈9.5 | ≈9.5 | · | · | |
| السعر / القيمة الدفترية (الربع الأخير) | 9.2متوسط 5 سنوات ≈18.1 | ≈18.1 | · | · | |
| السعر / التدفق النقدي الحر (سنوي حالي) | 12.2متوسط 5 سنوات ≈45.7 | ≈45.7 | · | · | |
| السعر / التدفق النقدي (سنوي حالي) | 10.0متوسط 5 سنوات ≈33.9 | ≈33.9 | · | · | |
| القيمة المؤسسية / الإيرادات (سنوي حالي) | 3.8 | · | · | · | |
| القيمة المؤسسية / التدفق النقدي الحر (سنوي حالي) | 15.3 | · | · | · | |
| السعر / القيمة الدفترية الملموسة (الربع الأخير) | 12.9متوسط 5 سنوات ≈180.4 | ≈180.4 | · | · | |
| PEG Ratio (نسبة السعر إلى الأرباح إلى النمو (PEG)) | ≈1.0 | · | · | · |
يتم حساب الوسيط النظير على أساس موحد لكل مقياس وقد لا يتطابق دائمًا مع الأساس السنوي الحالي/الربع الأخير المعروض لهذا السهم.
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
| المقياس | اتجاه 5 سنوات | ZTS | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| EBITDA Margin (هامش EBITDA) | 5.1%متوسط 5 سنوات ≈5.6% | ≈5.6% | 8.3% | ضعيف | |
| هامش ما قبل الضريبة (سنوي حالي) | 34.4%متوسط 5 سنوات ≈33.7% | ≈33.7% | 15.0% | من الدرجة الأولى | |
| هامش صافي الربح (سنوي حالي) | 27.5%متوسط 5 سنوات ≈27.0% | ≈27.0% | 10.4% | من الدرجة الأولى | |
| العائد على الأصول (سنوي حالي) | 17.7%متوسط 5 سنوات ≈16.2% | ≈16.2% | 9.8% | من الدرجة الأولى | |
| ROE (سنوي حالي) | 64.4%متوسط 5 سنوات ≈52.6% | ≈52.6% | 25.3% | من الدرجة الأولى |
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
| المقياس | اتجاه 5 سنوات | ZTS | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| الدين / حقوق الملكية (الربع الأخير) | 2.9متوسط 5 سنوات ≈1.7 | ≈1.7 | 0.9 | ديون مرتفعة | |
| النسبة الحالية (الربع الأخير) | 3.1متوسط 5 سنوات ≈2.9 | ≈2.9 | 1.6 | سيولة قوية | |
| النسبة السريعة (الربع الأخير) | 1.6متوسط 5 سنوات ≈0.6 | ≈0.6 | 0.8 | سيولة قوية | |
| الدين طويل الأجل / حقوق الملكية (الربع الأخير) | 2.9متوسط 5 سنوات ≈1.6 | ≈1.6 | 0.9 | ديون مرتفعة |
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
| المقياس | اتجاه 5 سنوات | ZTS | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| Revenue YoY (الإيرادات مقارنة بالعام السابق) | 2.3%متوسط 5 سنوات ≈7.3% | ≈7.3% | · | · | |
| Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات) | 5.4%متوسط 5 سنوات ≈6.7% | ≈6.7% | · | · | |
| Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات) | 7.2% | · | · | · | |
| EPS YoY (ربحية السهم على أساس سنوي) | 10.1%متوسط 5 سنوات ≈12.2% | ≈12.2% | · | · | |
| Net Income YoY (صافي الدخل مقارنة بالعام السابق) | 7.5%متوسط 5 سنوات ≈10.5% | ≈10.5% | · | · | |
| EPS CAGR 3Y (متوسط نمو ربحية السهم السنوي لـ 3 سنوات) | 10.3%متوسط 5 سنوات ≈11.0% | ≈11.0% | · | · | |
| EPS CAGR 5Y (متوسط نمو ربحية السهم السنوي لـ 5 سنوات) | 12.0% | · | · | · | |
| Net Income CAGR 3Y (متوسط نمو صافي الدخل السنوي لـ 3 سنوات) | 8.1%متوسط 5 سنوات ≈9.2% | ≈9.2% | · | · | |
| Net Income CAGR 5Y (متوسط نمو صافي الدخل السنوي لـ 5 سنوات) | 10.3% | · | · | · |
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
| المقياس | اتجاه 5 سنوات | ZTS | متوسط 5 سنوات | متوسط الأقران | الحكم |
|---|---|---|---|---|---|
| Asset Turnover (دوران الأصول) | 0.6متوسط 5 سنوات ≈0.6 | ≈0.6 | 0.5 | من الدرجة الأولى | |
| Inventory Turnover (دوران المخزون) | 1.1متوسط 5 سنوات ≈1.1 | ≈1.1 | 1.5 | ضعيف | |
| Receivables Turnover (دوران المستحقات) | 6.5متوسط 5 سنوات ≈6.9 | ≈6.9 | 5.6 | من الدرجة الأولى | |
| Revenue / Employee (الإيرادات / الموظف) | ≈$652.9K | · | · | · |
القيمة · ≈ متوسط 5 سنوات · متوسط الصناعة · حكم مقارنة بالمتوسط
التوزيعات العائد، نسبة التوزيع، تاريخ توزيع الأرباح، معدل النمو السنوي المركب لمدة 5 سنوات
العائد السنوي≈$2.12
5Y Div CAGR≈20.1%
سلسلة النمو≈11
| تاريخ الاستحقاق | المبلغ | العملة | العائد |
|---|---|---|---|
| يوليو 20, 2026 | $0,53 | USD | ≈2.7% |
| إبريل 20, 2026 | $0,53 | USD | ≈1.7% |
| يناير 20, 2026 | $0,53 | USD | ≈1.6% |
| أكتوبر 31, 2025 | $0,50 | USD | ≈1.4% |
| يوليو 18, 2025 | $0,50 | USD | ≈1.3% |
| إبريل 21, 2025 | $0,50 | USD | ≈1.3% |
| يناير 21, 2025 | $0,50 | USD | ≈1.1% |
| أكتوبر 31, 2024 | $0,43 | USD | ≈0.97% |
| يوليو 18, 2024 | $0,43 | USD | ≈0.93% |
| إبريل 18, 2024 | $0,43 | USD | ≈1.1% |
| يناير 18, 2024 | $0,43 | USD | ≈0.82% |
| أكتوبر 31, 2023 | $0,38 | USD | ≈0.96% |
| يوليو 20, 2023 | $0,38 | USD | ≈0.84% |
| إبريل 20, 2023 | $0,38 | USD | ≈0.80% |
| يناير 19, 2023 | $0,38 | USD | ≈0.83% |
| أكتوبر 31, 2022 | $0,33 | USD | ≈0.86% |
| يوليو 20, 2022 | $0,33 | USD | ≈0.70% |
| إبريل 20, 2022 | $0,33 | USD | ≈0.61% |
| يناير 19, 2022 | $0,33 | USD | ≈0.54% |
| أكتوبر 28, 2021 | $0,25 | USD | ≈0.47% |
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
2.5%
التقرير القادم
نوفمبر 05, 2026
| الفترة | تقرير | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|---|
| 30 يونيو، 2026 | أغسطس 6, 2026 | $1.87 | $1.87 | -0.22% |
| 31 مارس، 2026 | $1.53 | $1.63 | -6.2% | |
| 31 ديسمبر، 2025 | $1.48 | $1.42 | 4.5% | |
| 30 سبتمبر، 2025 | $1.70 | $1.64 | 3.8% | |
| 30 يونيو، 2025 | $1.76 | $1.63 | 7.8% | |
| 31 مارس، 2025 | $1.48 | $1.41 | 5.2% |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B | $6.67B | $6.26B | $5.83B | $5.31B | $4.89B | $4.76B | $4.79B | |
| Cost of Revenue | $2.67B | $2.72B | $2.56B | $2.45B | $2.30B | $2.06B | $1.99B | $1.91B | $1.77B | $1.67B | $1.74B | $1.72B | |
| SG&A Expense | $2.38B | $2.32B | $2.15B | $2.01B | $2.00B | $1.73B | $1.64B | $1.48B | $1.33B | $1.36B | $1.53B | $1.64B | |
| Interest Expense | $222M | $225M | $239M | $221M | $224M | $231M | $223M | $206M | $175M | $166M | $124M | $117M | |
| Other Non-op | $-6M | $-4M | $-2M | $14M | $-4M | $-5M | $0 | $15M | $1M | $2M | $5M | $-3M | |
| Pretax Income | $3.36B | $3.13B | $2.94B | $2.66B | $2.49B | $2.00B | $1.80B | $1.69B | $1.52B | $1.23B | $545M | $820M | |
| Income Tax | $687M | $637M | $596M | $545M | $454M | $360M | $301M | $266M | $663M | $409M | $206M | $233M | |
| Net Income | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B | $1.64B | $1.50B | $1.43B | $864M | $821M | $339M | $583M | |
| EPS (Basic) | $6.03 | $5.47 | $5.08 | $4.51 | $4.29 | $3.44 | $3.14 | $2.96 | $1.76 | $1.66 | $0.68 | $1.16 | |
| EPS (Diluted) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 | $0.68 | $1.16 | |
| Shares (Basic) | 443,443,000 | 454,200,000 | 461,172,000 | 468,891,000 | 474,348,000 | 475,502,000 | 478,128,000 | 483,063,000 | 489,918,000 | 495,715,000 | 499,707,000 | 501,055,000 | |
| Shares (Diluted) | 443,835,000 | 454,848,000 | 462,269,000 | 470,385,000 | 476,717,000 | 478,569,000 | 481,787,000 | 486,898,000 | 493,161,000 | 498,225,000 | 502,019,000 | 502,025,000 | |
| EBITDA | $487M | $497M | $491M | $465M | $448M | $441M | $412M | $308M | $242M | $240M | $199M | $204M |
الميزانية العمومية
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.45B | $1.99B | $2.04B | $3.58B | $3.48B | $3.60B | $1.93B | $1.60B | $1.56B | $727M | $1.15B | $882M | |
| Short-term Investments | $0 | · | · | · | · | · | $0 | $99M | $0 | · | · | · | |
| Receivables | $1.41B | $1.32B | $1.30B | $1.22B | $1.13B | $1.01B | $1.09B | $1.04B | $998M | $913M | $937M | $980M | |
| Inventory | $2.46B | $2.31B | $2.56B | $2.35B | $1.92B | $1.63B | $1.41B | $1.39B | $1.43B | $1.50B | $1.47B | $1.29B | |
| Other Current Assets | $450M | $377M | $434M | $365M | $389M | $366M | $318M | $271M | $228M | $248M | $201M | $205M | |
| Current Assets | $6.77B | $5.99B | $6.34B | $7.51B | $6.93B | $6.61B | $4.75B | $4.40B | $4.22B | $3.39B | $3.83B | $3.46B | |
| PP&E (Net) | $3.69B | $3.39B | $3.20B | $2.75B | $2.42B | $2.20B | $1.94B | $1.66B | $1.44B | $1.38B | $1.31B | $1.32B | |
| PP&E (Gross) | $6.61B | $6.03B | $5.80B | $5.05B | $4.49B | $4.15B | $3.68B | $3.26B | $2.91B | $2.74B | $2.52B | $2.46B | |
| Accum. Depreciation | $2.94B | $2.63B | $2.59B | $2.30B | $2.07B | $1.95B | $1.74B | $1.60B | $1.47B | $1.36B | $1.21B | $1.15B | |
| Goodwill | $2.77B | $2.72B | $2.76B | $2.75B | $2.68B | $2.69B | $2.59B | $2.52B | $1.51B | $1.48B | $1.46B | $976M | |
| Intangibles | $998M | $1.13B | $1.34B | $1.38B | $1.47B | $1.71B | $1.89B | $2.05B | $1.27B | $1.23B | $1.19B | $727M | |
| Other Non-current Assets | $327M | $250M | $206M | $147M | $111M | $106M | $98M | $94M | $75M | $73M | $49M | $48M | |
| Total Assets | $15.49B | $14.24B | $14.29B | $14.93B | $13.90B | $13.61B | $11.54B | $10.78B | $8.59B | $7.65B | $7.91B | $6.59B | |
| Accounts Payable | $445M | $433M | $411M | $405M | $436M | $457M | $301M | $313M | $261M | $265M | $293M | $290M | |
| Accrued Liabilities | $852M | $746M | $683M | $682M | $710M | $556M | $543M | $487M | $432M | $464M | $676M | $475M | |
| Short-term Debt | $0 | $0 | $3M | $2M | $0 | $4M | $0 | $9M | $0 | $0 | $0 | $0 | |
| Current Liabilities | $2.17B | $3.41B | $1.89B | $3.17B | $1.80B | $2.17B | $1.81B | $1.22B | $1.09B | $1.12B | $1.78B | $1.09B | |
| Capital Leases | $197M | $174M | $188M | $186M | $151M | $163M | $164M | $0 | · | · | · | · | |
| Deferred Tax | $137M | $167M | $146M | $142M | $320M | $378M | $434M | $474M | $380M | $244M | $264M | $277M | |
| Other Non-current Liabilities | $250M | $222M | $237M | $217M | $239M | $270M | $229M | $187M | $201M | $248M | $251M | $207M | |
| Total Liabilities | $12.07B | $9.47B | $9.29B | $10.52B | $9.36B | $9.84B | $8.84B | $8.59B | $6.80B | $6.15B | $6.82B | $5.25B | |
| Long-term Debt | $9.04B | $6.57B | $6.56B | $7.90B | $6.59B | $7.20B | $6.45B | $6.44B | $4.95B | $4.47B | $4.86B | $3.62B | |
| Total Debt | $9.04B | $6.57B | $6.57B | $7.90B | $6.59B | $7.20B | $6.45B | $6.45B | $4.95B | $4.47B | $4.86B | · | |
| Common Stock | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Paid-in Capital | $1.10B | $1.18B | $1.13B | $1.09B | $1.07B | $1.06B | $1.04B | $1.03B | $1.01B | $1.02B | $1.01B | $958M | |
| Retained Earnings | $13.80B | $11.97B | $10.29B | $8.67B | $7.19B | $5.66B | $4.43B | $3.27B | $2.11B | $1.48B | $876M | $709M | |
| Treasury Stock | $10.69B | $7.45B | $5.60B | $4.54B | $2.95B | $2.23B | $2.04B | $1.49B | $852M | $421M | $203M | $0 | |
| AOCI | $-804M | $-940M | $-839M | $-817M | $-764M | $-730M | $-726M | $-629M | $-505M | $-598M | $-622M | $-361M | |
| Stockholders' Equity | $3.42B | $4.77B | $5.00B | $4.41B | $4.54B | $3.77B | $2.71B | $2.19B | $1.79B | $1.50B | $1.07B | $1.31B | |
| Liabilities + Equity | $15.49B | $14.24B | $14.29B | $14.93B | $13.90B | $13.61B | $11.54B | $10.78B | $8.59B | $7.65B | $7.91B | $6.59B | |
| Shares Outstanding | 424,927,535 | 448,473,073 | 458,367,358 | 463,808,059 | 472,574,090 | 475,317,751 | 475,528,210 | 479,562,326 | 486,130,461 | 492,855,297 | 497,400,113 | 501,327,524 |
التدفق النقدي
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $487M | $497M | $491M | $465M | $448M | $441M | $412M | $308M | $242M | $240M | $199M | $204M | |
| Stock-based Comp | $83M | $74M | $60M | $62M | $58M | $59M | $67M | $53M | $44M | $37M | $43M | $32M | |
| Deferred Tax | $-52M | $-338M | $-61M | $-286M | $-80M | $-62M | $-79M | $-112M | $127M | $-55M | $-85M | $-49M | |
| Amort. of Intangibles | $157M | $170M | $185M | $193M | $204M | $230M | $237M | $157M | $100M | $95M | $64M | $63M | |
| Restructuring | $49M | $43M | $46M | $6M | $33M | $8M | $33M | $26M | $13M | $2M | $301M | $17M | |
| Other Non-cash | $-287M | $234M | $-481M | $-443M | $-250M | $50M | $-105M | $113M | $69M | $-330M | $168M | $-144M | |
| Operating Cash Flow | $2.90B | $2.95B | $2.35B | $1.91B | $2.21B | $2.13B | $1.79B | $1.79B | $1.35B | $713M | $664M | $626M | |
| CapEx | $621M | $655M | $732M | $586M | $477M | $453M | $460M | $338M | $224M | $216M | $224M | $180M | |
| Investing Cash Flow | $-748M | $-315M | $-777M | $-883M | $-458M | $-572M | $-504M | $-2.26B | $-270M | $-214M | $-1.11B | $-187M | |
| Net Debt Issued | $-1.35B | $0 | $-1.35B | $0 | $-600M | $-500M | $0 | $0 | $-750M | $-400M | · | · | |
| Stock Repurchased | $3.23B | $1.86B | $1.09B | $1.59B | $743M | $250M | $626M | $698M | $500M | $300M | $203M | $0 | |
| Net Stock Activity | $-3.23B | $-1.86B | $-1.09B | $-1.59B | $-743M | $-250M | $-626M | $-698M | $-500M | $-300M | $-203M | · | |
| Financing Cash Flow | $-1.87B | $-2.66B | $-3.11B | $-904M | $-1.86B | $123M | $-951M | $533M | $-251M | $-903M | $755M | $-154M | |
| Net Change in Cash | $325M | $-54M | $-1.54B | $96M | $-119M | $1.67B | $332M | $38M | $837M | $-427M | $272M | $272M | |
| Taxes Paid | $715M | $892M | $754M | $638M | $548M | $418M | $418M | $336M | $455M | $408M | $224M | $278M | |
| Free Cash Flow | $2.28B | $2.30B | $1.62B | $1.33B | $1.74B | $1.67B | $1.33B | $1.45B | $1.12B | $497M | $440M | $446M | |
| Levered FCF | $2.11B | $2.12B | $1.43B | $1.15B | $1.55B | $1.48B | $1.15B | $1.28B | $1.02B | $386M | $363M | $362M |
الربحية
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 28.2% | 26.9% | 27.4% | 26.2% | 26.2% | 24.5% | 24.0% | 24.5% | 16.3% | 16.8% | 7.1% | 12.2% | |
| Pretax Margin | 35.5% | 33.9% | 34.4% | 32.9% | 32.0% | 29.9% | 28.8% | 29.0% | 28.7% | 25.1% | 11.4% | 17.1% | |
| EBITDA Margin | 5.1% | 5.4% | 5.8% | 5.8% | 5.8% | 6.6% | 6.6% | 5.3% | 4.6% | 4.9% | 4.2% | 4.3% | |
| ROA | 18.0% | 17.4% | 16.1% | 14.7% | 14.8% | 13.0% | 13.4% | 14.7% | 10.6% | 10.5% | 4.7% | · | |
| ROE | 66.0% | 50.9% | 49.9% | 47.2% | 49.0% | 50.6% | 58.6% | 66.4% | 52.9% | 64.3% | 28.5% | · |
السيولة والملاءة
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.0 | 1.8 | 3.4 | 2.4 | 3.9 | 3.0 | 2.6 | 3.6 | 3.9 | 3.0 | 2.2 | · | |
| Quick Ratio | 0.7 | 0.4 | 0.7 | 0.4 | 0.6 | 0.5 | 0.6 | 0.9 | 2.3 | 1.5 | 1.2 | · | |
| Debt / Equity | 2.7 | 1.4 | 1.3 | 1.8 | 1.5 | 1.9 | 2.4 | 3.0 | 2.8 | 3.0 | 4.6 | · | |
| LT Debt / Equity | 2.7 | 1.1 | 1.3 | 1.5 | 1.5 | 1.7 | 2.2 | 2.9 | 2.8 | 3.0 | 4.2 | · |
الكفاءة
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | · | |
| Inventory Turnover | 1.1 | 1.1 | 1.0 | 1.1 | 1.3 | 1.4 | 1.4 | 1.4 | 1.2 | 1.1 | 1.3 | · | |
| Receivables Turnover | 6.5 | 7.1 | 6.8 | 6.9 | 7.2 | 6.4 | 5.9 | 5.7 | 5.6 | 5.3 | 5.0 | · |
لكل سهم
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.84 | $10.64 | $10.90 | $9.50 | $9.61 | $7.93 | $5.69 | $4.56 | $3.64 | $3.02 | $2.15 | · | |
| Revenue / Share | $21.33 | $20.35 | $18.48 | $17.18 | $16.31 | $13.95 | $12.99 | $11.96 | $10.76 | $9.81 | $9.49 | $9.53 | |
| Cash Flow / Share | $6.54 | $6.49 | $5.09 | $4.06 | $4.64 | $4.44 | $3.73 | $3.68 | $2.73 | $1.43 | $1.32 | $1.25 | |
| Cash / Share | · | · | · | · | · | · | · | · | $3.22 | $1.48 | $2.32 | · | |
| Dividend Paid / Share | $2.03 | $1.80 | $1.56 | $1.35 | $1.07 | $0.85 | $0.69 | $0.54 | $0.44 | $0.39 | $0.34 | $0.30 | |
| EPS (TTM) | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 | $0.68 | $1.16 |
معدلات النمو
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 2.3% | 8.3% | 5.7% | 3.9% | 16.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.4% | 6.0% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 10.1% | 7.9% | 12.9% | 5.1% | 24.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 10.3% | 8.6% | 14.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 12.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 7.5% | 6.1% | 10.9% | 3.8% | 24.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 8.1% | 6.9% | 12.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 10.3% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا)
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B | $6.67B | $6.26B | $5.83B | $5.31B | $4.89B | $4.76B | $4.79B | |
| Net Income TTM | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B | $1.64B | $1.50B | $1.43B | $864M | $821M | $339M | $583M | |
| Market Cap | $53.46B | $73.07B | $90.47B | $67.97B | $115.32B | $78.67B | $62.94B | $41.02B | $35.02B | $26.38B | $23.84B | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $38.41B | $30.12B | $27.54B | · | |
| P/E | 20.9 | 29.8 | 38.9 | 32.6 | 57.1 | 48.4 | 42.6 | 29.2 | 41.2 | 32.4 | 70.5 | 37.1 | |
| P/S | 5.6 | 7.9 | 10.6 | 8.4 | 14.8 | 11.8 | 10.1 | 7.0 | 6.6 | 5.4 | 5.0 | · | |
| P/B | 16.1 | 15.3 | 18.1 | 15.4 | 25.4 | 20.9 | 23.2 | 18.8 | 19.8 | 17.7 | 22.3 | · | |
| P / Tangible Book | · | 79.5 | 100.5 | 243.6 | 298.0 | · | · | · | · | · | · | · | |
| P / Cash Flow | 18.4 | 24.7 | 38.4 | 35.5 | 52.1 | 37.0 | 35.1 | 22.9 | 26.0 | 37.0 | 35.9 | · | |
| P / FCF | 23.4 | 31.8 | 55.8 | 51.3 | 66.4 | 47.0 | 47.1 | 28.3 | 31.2 | 53.1 | 54.2 | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 158.7 | 125.5 | 138.4 | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 34.2 | 60.6 | 62.6 | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 7.2 | 6.2 | 5.8 | · | |
| Earnings Yield | 4.8% | 3.4% | 2.6% | 3.1% | 1.8% | 2.1% | 2.4% | 3.4% | 2.4% | 3.1% | 1.4% | 2.7% |
قائمة الدخل
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.47B | $2.26B | $2.39B | $2.40B | $2.47B | $2.20B | $2.32B | $2.39B | $2.36B | $2.19B | $2.21B | $2.15B | $2.18B | $2.00B | $2.04B | $2.00B | |
| Cost of Revenue | $673M | $641M | $712M | $683M | $664M | $618M | $707M | $701M | $668M | $643M | $728M | $638M | $607M | $588M | $653M | $607M | |
| SG&A Expense | $592M | $588M | $619M | $579M | $614M | $574M | $625M | $565M | $581M | $547M | $565M | $525M | $556M | $505M | $514M | $501M | |
| Interest Expense | $61M | $62M | $57M | $58M | $53M | $54M | $51M | $57M | $59M | $58M | $59M | $59M | $58M | $63M | $62M | $53M | |
| Other Non-op | $-2M | $-1M | $-8M | $0 | $-1M | $3M | $1M | $-2M | $2M | $-5M | $5M | $-4M | $2M | $-5M | $6M | $1M | |
| Pretax Income | $866M | $758M | $761M | $887M | $912M | $773M | $732M | $874M | $780M | $747M | $650M | $717M | $872M | $697M | $592M | $667M | |
| Income Tax | $175M | $157M | $158M | $166M | $186M | $171M | $151M | $182M | $156M | $148M | $127M | $121M | $202M | $146M | $132M | $139M | |
| Net Income | $691M | $601M | $603M | $721M | $726M | $602M | $581M | $682M | $624M | $599M | $525M | $596M | $671M | $552M | $461M | $529M | |
| EPS (Basic) | $1.65 | $1.42 | $1.38 | $1.63 | $1.63 | $1.34 | $1.28 | $1.51 | $1.37 | $1.31 | $1.15 | $1.29 | $1.45 | $1.19 | $0.99 | $1.13 | |
| EPS (Diluted) | $1.65 | $1.42 | $1.37 | $1.63 | $1.63 | $1.34 | $1.29 | $1.50 | $1.37 | $1.31 | $1.14 | $1.29 | $1.45 | $1.19 | $0.98 | $1.13 | |
| Shares (Basic) | 417,600,000 | 422,100,000 | · | 442,900,000 | 445,100,000 | 447,600,000 | · | 452,900,000 | 455,500,000 | 458,000,000 | · | 460,300,000 | 461,900,000 | 463,500,000 | · | 467,800,000 | |
| Shares (Diluted) | 417,700,000 | 422,400,000 | · | 443,200,000 | 445,500,000 | 448,000,000 | · | 453,500,000 | 456,000,000 | 458,800,000 | · | 461,400,000 | 462,900,000 | 464,600,000 | · | 469,100,000 | |
| EBITDA | $119M | $119M | · | $124M | $123M | $119M | · | $121M | $127M | $126M | · | $124M | $121M | $120M | · | $115M |
الميزانية العمومية
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.48B | $1.94B | · | $2.08B | $1.44B | $1.72B | · | $1.71B | $1.57B | $1.98B | · | $1.75B | $1.72B | $2.11B | · | $2.51B | |
| Short-term Investments | $200M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $1.57B | $1.51B | $1.59B | $1.54B | $1.54B | $1.36B | $1.32B | $1.41B | $1.38B | $1.29B | · | $1.26B | $1.32B | $1.19B | · | $1.19B | |
| Inventory | $2.57B | $2.55B | $2.43B | $2.46B | $2.44B | $2.37B | $2.31B | $2.42B | $2.45B | $2.65B | · | $2.74B | $2.70B | $2.56B | · | $2.30B | |
| Other Current Assets | $535M | $477M | $436M | $493M | $509M | $430M | $377M | $427M | $467M | $440M | · | $467M | $443M | $411M | · | $552M | |
| Current Assets | $6.36B | $6.47B | $6.77B | $6.58B | $5.92B | $5.88B | $5.99B | $6.28B | $6.20B | $6.36B | · | $6.22B | $6.18B | $6.27B | · | $6.55B | |
| PP&E (Net) | $3.76B | $3.72B | $3.68B | $3.60B | $3.54B | $3.44B | $3.39B | $3.30B | $3.20B | $3.25B | · | $3.09B | $3.01B | $2.91B | · | $2.62B | |
| PP&E (Gross) | · | · | $6.61B | · | · | · | $6.03B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3.07B | $3.00B | $2.92B | $2.87B | $2.80B | $2.70B | $2.63B | $2.66B | $2.59B | $2.67B | · | $2.53B | $2.45B | $2.37B | · | $2.23B | |
| Goodwill | $2.77B | $2.78B | $2.77B | $2.76B | $2.76B | $2.72B | $2.72B | $2.74B | $2.74B | $2.76B | $2.76B | $2.76B | $2.71B | $2.74B | $2.75B | $2.69B | |
| Intangibles | $918M | $959M | $998M | $1.04B | $1.07B | $1.08B | $1.13B | $1.19B | $1.23B | $1.29B | · | $1.40B | $1.25B | $1.31B | · | $1.32B | |
| Other Non-current Assets | $384M | $351M | $328M | $293M | $267M | $232M | $250M | $215M | $210M | $227M | · | $216M | $173M | $143M | · | $161M | |
| Total Assets | $15.08B | $15.15B | $15.47B | $15.16B | $14.48B | $14.10B | $14.24B | $14.36B | $14.16B | $14.35B | · | $14.11B | $13.75B | $13.75B | · | $13.67B | |
| Accounts Payable | $452M | $507M | $487M | $410M | $508M | $420M | $433M | $404M | $420M | $405M | · | $388M | $464M | $424M | · | $373M | |
| Accrued Liabilities | · | · | $852M | · | · | · | $746M | · | · | · | · | · | · | · | · | · | |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $24M | · | $2M | $2M | $3M | · | $3M | |
| Current Liabilities | $2.06B | $2.05B | $2.23B | $1.81B | $3.37B | $3.38B | $3.41B | $1.70B | $1.80B | $1.91B | · | $1.61B | $1.77B | $1.92B | · | $2.88B | |
| Capital Leases | $190M | $193M | $196M | $204M | $210M | $173M | $174M | $181M | $181M | $184M | · | $191M | $188M | $180M | · | $186M | |
| Deferred Tax | $122M | $130M | $139M | $147M | $156M | $161M | $167M | $172M | $175M | $136M | · | $160M | $121M | $131M | · | $256M | |
| Other Non-current Liabilities | $220M | $219M | $248M | $264M | $274M | $220M | $222M | $220M | $222M | $228M | · | $259M | $217M | $216M | · | $239M | |
| Total Liabilities | $11.93B | $11.92B | $12.14B | $9.76B | $9.50B | $9.44B | $9.47B | $9.12B | $9.21B | $9.30B | · | $9.03B | $9.13B | $9.26B | · | $9.01B | |
| Long-term Debt | · | · | $9.04B | $7.07B | $6.58B | $6.58B | $6.57B | · | · | · | · | $6.55B | $6.55B | $6.56B | · | $6.56B | |
| Total Debt | $9.05B | $9.04B | · | $7.07B | $6.58B | $6.58B | · | $6.57B | $6.56B | $6.59B | · | $6.55B | $6.56B | $6.56B | · | $6.56B | |
| Common Stock | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $5M | $5M | $5M | · | $5M | |
| Paid-in Capital | $1.13B | $1.10B | $1.10B | $1.22B | $1.20B | $1.18B | $1.18B | $1.16B | $1.15B | $1.13B | · | $1.12B | $1.10B | $1.08B | · | $1.07B | |
| Retained Earnings | $14.65B | $14.18B | $13.74B | $13.59B | $12.87B | $12.38B | $11.97B | $11.81B | $11.12B | $10.70B | · | $10.14B | $9.54B | $9.04B | · | $8.53B | |
| Treasury Stock | $11.85B | $11.29B | $10.69B | $8.61B | $8.23B | $7.89B | $7.45B | $6.89B | $6.46B | $5.93B | · | $5.37B | $5.13B | $4.81B | · | $4.14B | |
| AOCI | $-796M | $-772M | $-834M | $-818M | $-877M | $-1.02B | $-940M | $-851M | $-845M | $-841M | · | $-814M | $-895M | $-828M | · | $-809M | |
| Stockholders' Equity | $3.15B | $3.23B | $3.33B | $5.40B | $4.98B | $4.66B | $4.77B | $5.23B | $4.97B | $5.06B | · | $5.08B | $4.62B | $4.49B | · | $4.66B | |
| Liabilities + Equity | $15.08B | $15.15B | $15.47B | $15.16B | $14.48B | $14.10B | $14.24B | $14.36B | $14.16B | $14.35B | · | $14.11B | $13.75B | $13.75B | · | $13.67B | |
| Shares Outstanding | 414,154,046 | 420,348,495 | 424,927,535 | 441,464,339 | 443,945,593 | 446,040,205 | 448,473,073 | 451,549,789 | 453,812,361 | 456,947,205 | · | 459,524,713 | 460,750,652 | 462,495,343 | · | 466,442,095 |
التدفق النقدي
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $119M | $119M | $121M | $124M | $124M | $119M | $123M | $121M | $127M | $126M | $126M | $124M | $121M | $120M | $119M | $115M | |
| Stock-based Comp | $26M | $25M | $22M | $22M | $22M | $17M | $19M | $18M | $19M | $18M | $17M | $17M | $17M | $9M | $16M | $15M | |
| Deferred Tax | $-33M | $34M | $-48M | $-16M | $-7M | $14M | $-152M | $-42M | $-101M | $-43M | $-21M | $-14M | $-34M | $8M | $-176M | $-34M | |
| Amort. of Intangibles | $38M | $39M | $38M | $39M | $40M | $40M | $42M | $42M | $42M | $44M | $44M | $46M | $48M | $47M | $46M | $48M | |
| Restructuring | $75M | $20M | $16M | $4M | · | · | $-3M | $-2M | $37M | $11M | $8M | $13M | $5M | $20M | $1M | · | |
| Other Non-cash | · | $-378M | · | · | · | $-199M | · | · | · | $-105M | · | · | · | $-140M | · | · | |
| Operating Cash Flow | $655M | $401M | $893M | $938M | $486M | $515M | $905M | $951M | $502M | $595M | $897M | $724M | $183M | $549M | $741M | $526M | |
| CapEx | $117M | $110M | $161M | $133M | $178M | $178M | $216M | $167M | $132M | $140M | $198M | $145M | $166M | $223M | $171M | $154M | |
| Investing Cash Flow | $-300M | $-87M | $-166M | $-160M | $-247M | $-203M | $126M | $-178M | $-132M | $-131M | $-210M | $-271M | $-80M | $-216M | $-438M | $-124M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-1.35B | · | · | |
| Stock Repurchased | $584M | $606M | $2.06B | $394M | $338M | $443M | $553M | $433M | $533M | $339M | $235M | $250M | $324M | $283M | $405M | $377M | |
| Net Stock Activity | · | $-606M | · | · | · | $-443M | · | · | · | $-339M | · | · | · | $-283M | · | · | |
| Financing Cash Flow | $-813M | $-840M | $-495M | $-134M | $-564M | $-677M | $-745M | $-628M | $-763M | $-524M | $-397M | $-416M | $-494M | $-1.80B | $780M | $-529M | |
| Net Change in Cash | $-465M | $-509M | $228M | $649M | $-286M | $-332M | $273M | $140M | $-401M | $-66M | $287M | $37M | $-392M | $-1.47B | $1.07B | $-145M | |
| Taxes Paid | $380M | $50M | $133M | $107M | $428M | $60M | $235M | $176M | $422M | $59M | $168M | $128M | $438M | $20M | $167M | $155M | |
| Free Cash Flow | · | $291M | · | · | · | $438M | · | · | · | $455M | · | · | · | $326M | · | · | |
| Levered FCF | · | $242M | · | · | · | $396M | · | · | · | $408M | · | · | · | $276M | · | · |
الربحية
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 28.0% | 26.6% | · | 30.0% | 29.2% | 28.4% | · | 28.6% | 26.4% | 27.4% | · | 27.7% | 30.8% | 27.6% | · | 26.4% | |
| Pretax Margin | 35.1% | 33.5% | · | 37.0% | 36.7% | 36.5% | · | 36.6% | 33.0% | 34.1% | · | 33.3% | 40.0% | 34.8% | · | 33.3% | |
| EBITDA Margin | 4.8% | 5.3% | · | 5.2% | 5.0% | 5.4% | · | 5.1% | 5.4% | 5.8% | · | 5.8% | 5.5% | 6.0% | · | 5.7% | |
| ROA | 4.7% | 4.1% | · | 4.9% | 5.0% | 4.4% | · | 4.8% | 4.5% | 4.3% | · | 4.3% | 4.9% | 4.0% | · | 3.9% | |
| ROE | 17.0% | 15.2% | · | 13.6% | 14.4% | 13.0% | · | 13.2% | 13.0% | 12.5% | · | 12.2% | 14.6% | 12.1% | · | 11.3% |
السيولة والملاءة
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.2 | · | 3.6 | 1.8 | 1.7 | · | 3.7 | 3.5 | 3.3 | · | 3.9 | 3.5 | 3.3 | · | 2.3 | |
| Quick Ratio | 1.6 | 1.7 | · | 2.0 | 0.9 | 0.9 | · | 1.8 | 1.6 | 1.7 | · | 1.9 | 1.7 | 1.7 | · | 1.3 | |
| Debt / Equity | 2.9 | 2.8 | · | 1.3 | 1.3 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.5 | · | 1.4 | |
| LT Debt / Equity | 2.9 | 2.8 | · | 1.3 | 1.1 | 1.1 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.5 | · | 1.1 |
الكفاءة
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.3 | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.6 | 1.6 | · | 1.6 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.8 | · | 1.8 | 1.7 | 1.7 | · | 1.7 |
لكل سهم
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.60 | $7.69 | · | $12.23 | $11.21 | $10.44 | · | $11.59 | $10.94 | $11.07 | · | $11.05 | $10.04 | $9.72 | · | $10.00 | |
| Revenue / Share | $5.91 | $5.36 | · | $5.42 | $5.52 | $4.96 | · | $5.27 | $5.18 | $4.77 | · | $4.66 | $4.71 | $4.30 | · | $4.27 | |
| Cash Flow / Share | · | $0.95 | · | · | · | $1.31 | · | · | · | $1.30 | · | · | · | $1.18 | · | · | |
| Cash / Share | $3.56 | $4.62 | · | $4.72 | $3.23 | $3.86 | · | $3.80 | $3.47 | $4.32 | · | $3.82 | $3.73 | $4.56 | · | $5.37 | |
| Dividend / Share | $0.53 | $0.53 | · | $0.00 | $0.50 | $0.50 | · | $0.00 | $0.43 | $0.43 | · | $0.00 | $0.38 | $0.38 | · | $0.00 | |
| EPS (TTM) | $6.07 | $6.05 | · | $5.89 | $5.76 | $5.50 | · | $5.32 | $5.11 | $5.19 | · | $4.91 | $4.75 | $4.42 | · | $4.38 |
التقييم (آخر 12 شهرًا)
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9.52B | $9.52B | · | $9.39B | $9.38B | $9.26B | · | $9.15B | $8.91B | $8.73B | · | $8.37B | $8.22B | $8.09B | · | $8.01B | |
| Net Income TTM | $2.62B | $2.65B | · | $2.63B | $2.59B | $2.49B | · | $2.43B | $2.34B | $2.39B | · | $2.28B | $2.21B | $2.07B | · | $2.07B | |
| Market Cap | $29.76B | $49.69B | · | $64.60B | $69.23B | $73.44B | · | $88.22B | $78.67B | $77.32B | · | $79.95B | $79.35B | $76.98B | · | $69.17B | |
| Enterprise Value | $37.13B | $56.79B | · | $69.58B | $74.38B | $78.30B | · | $93.08B | $83.66B | $81.93B | · | $84.75B | $84.19B | $81.43B | · | $73.22B | |
| P/E | 11.8 | 19.5 | · | 24.8 | 27.1 | 29.9 | · | 36.7 | 33.9 | 32.6 | · | 35.4 | 36.3 | 37.7 | · | 33.9 | |
| P/S | 3.1 | 5.2 | · | 6.9 | 7.4 | 7.9 | · | 9.6 | 8.8 | 8.9 | · | 9.6 | 9.7 | 9.5 | · | 8.6 | |
| P/B | 9.5 | 15.4 | · | 12.0 | 13.9 | 15.8 | · | 16.9 | 15.8 | 15.3 | · | 15.7 | 17.2 | 17.1 | · | 14.8 | |
| P / Tangible Book | · | · | · | 40.5 | 60.5 | 85.7 | · | 67.7 | 78.6 | 77.0 | · | 87.1 | 120.4 | 174.2 | · | 106.1 | |
| P / Cash Flow | · | 123.9 | · | · | · | 125.1 | · | · | · | 129.9 | · | · | · | 140.2 | · | · | |
| EV / Revenue | 3.9 | 6.0 | · | 7.4 | 7.9 | 8.5 | · | 10.2 | 9.4 | 9.4 | · | 10.1 | 10.2 | 10.1 | · | 9.1 | |
| Earnings Yield | 8.5% | 5.1% | · | 4.0% | 3.7% | 3.3% | · | 2.7% | 2.9% | 3.1% | · | 2.8% | 2.8% | 2.7% | · | 2.9% |
أحدث فترة على اليسار · القيم الفارغة معروضة كـ ·
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| الإيرادات | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B |
| صافي الدخل | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B |
| EPS المخفف | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 |
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | 2.7 | 1.4 | 1.3 | 1.8 | 1.5 |
| النسبة الحالية | 3.0 | 1.8 | 3.4 | 2.4 | 3.9 |
| النسبة السريعة | 0.7 | 0.4 | 0.7 | 0.4 | 0.6 |
| المقياس | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $2.28B | $2.30B | $1.62B | $1.33B | $1.74B |
الملاك المؤسسيون (13F) 1578 مقدمي إقرار · $35.8B إجمالي · حتى تاريخ 30 سبتمبر، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
حائزون
1578
القيمة المحتفظ بها
$35.8B
مراكز جديدة
170
المراكز الخارجة
318
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 170 (-31 مقابل الربع السابق) | 318 (+136 مقابل الربع السابق) | 521 (-88 مقابل الربع السابق) | 585 (-42 مقابل الربع السابق) | -6.7M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6011802148 | 47780974 | 16,82% | الأسهم |
| BlackRock, Inc. | $2833452809 | 39430181 | 7,93% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $1870370930 | 26027984 | 5,23% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1714611578 | 23860445 | 4,80% | الأسهم |
| STATE STREET CORP | $1413322575 | 19667723 | 3,95% | الأسهم |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $1142064009 | 15892903 | 3,19% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $951789721 | 13289622 | 2,66% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $677201094 | 9423895 | 1,89% | الأسهم |
| MORGAN STANLEY | $638034469 | 8878849 | 1,78% | الأسهم |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $519929070 | 4398351 | 1,45% | الأسهم |
| NORDEA INVESTMENT MANAGEMENT AB | $471698956 | 6592578 | 1,32% | الأسهم |
| JANUS HENDERSON GROUP PLC | $437568419 | 3701747 | 1,22% | الأسهم |
| DEUTSCHE BANK AG\ | $420505821 | 5851737 | 1,18% | الأسهم |
| NORTHERN TRUST CORP | $398264934 | 5542234 | 1,11% | الأسهم |
| Invesco Ltd. | $396884095 | 5523018 | 1,11% | الأسهم |
| FIL Ltd | $386734926 | 5381783 | 1,08% | الأسهم |
| NORGES BANK | $337012405 | 4689847 | 0,94% | الأسهم |
| VAN ECK ASSOCIATES CORP | $305558780 | 4252140 | 0,85% | الأسهم |
| FLOSSBACH VON STORCH SE | $302600879 | 4210978 | 0,85% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $287726761 | 4003981 | 0,80% | الأسهم |
| Amundi | $286622090 | 3988618 | 0,80% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $282045207 | 3924926 | 0,79% | الأسهم |
| UBS Group AG | $261803299 | 3643241 | 0,73% | الأسهم |
| Legal & General Group Plc | $256352499 | 3567388 | 0,72% | الأسهم |
| Diamond Hill Capital Management, LLC (Investment Advisor) | $255637351 | 3557436 | 0,72% | الأسهم |
| CIBC Private Wealth Group LLC | $246008713 | 1681306 | 0,69% | الأسهم |
| Bank of New York Mellon Corp | $238741846 | 3322319 | 0,67% | الأسهم |
| GOLDMAN SACHS GROUP INC | $229937577 | 3199799 | 0,64% | الأسهم |
| CITADEL ADVISORS LLC | $229108579 | 3188263 | 0,64% | الأسهم |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $225456582 | 3137442 | 0,63% | الأسهم |
| JPMORGAN CHASE & CO | $192268534 | 2624825 | 0,54% | الأسهم |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $173617784 | 2416056 | 0,49% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $170008975 | 2365836 | 0,48% | الأسهم |
| Ruane, Cunniff & Goldfarb L.P. | $169108138 | 2353300 | 0,47% | الأسهم |
| BARCLAYS PLC | $165474682 | 2302737 | 0,46% | الأسهم |
| Qube Research & Technologies Ltd | $163792869 | 2279333 | 0,46% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $156216242 | 2173278 | 0,44% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $152540744 | 2122749 | 0,43% | الأسهم |
| JANE STREET GROUP, LLC | $144534676 | 2011337 | 0,40% | الأسهم |
| BRANDES INVESTMENT PARTNERS, LP | $138737455 | 1930651 | 0,39% | الأسهم |
| HSBC HOLDINGS PLC | $132131854 | 1839811 | 0,37% | الأسهم |
| BLS Capital Fondsmaeglerselskab A/S | $131538868 | 1830488 | 0,37% | الأسهم |
| ROYAL BANK OF CANADA | $131385000 | 1828326 | 0,37% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $130336722 | 1813759 | 0,36% | الأسهم |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | $130169165 | 1864087 | 0,36% | الأسهم |
| WELLS FARGO & COMPANY/MN | $130014751 | 1809278 | 0,36% | الأسهم |
| Man Group plc | $129707516 | 1805003 | 0,36% | الأسهم |
| Nuveen, LLC | $129322602 | 1799647 | 0,36% | الأسهم |
| BANQUE PICTET & CIE SA | $128888455 | 1793605 | 0,36% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $125134922 | 1741371 | 0,35% | الأسهم |
الناشطون والمالكون بنسبة 5%+ 2 حيازتان
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Pershing Square Capital Management, L.P., PS Management GP, LLC, William A. Ackman ×7 إيداعات | 8 يوليو، 2016 | · | إيداع أولي | · | SEC |
| Sachem Head Capital Management LP, Uncas GP LLC, Sachem Head GP LLC, Scott D. Ferguson ×2 إيداعات | 4 فبراير، 2015 | · | إيداع أولي | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
المطلعون على الشركة 52 من المطلعين · مسؤولون 30 · مديرون 21
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Kristin C Peck | Chief Executive Officer | 10 يوليو، 2026 A | 105068 | 0 | 2 | $-2540972 |
| James Saccaro | EVP, CFO & COO | 31 أغسطس، 2026 A | · | 0 | 0 | $0 |
| Wetteny Joseph | Chief Financial Officer | 10 يوليو، 2026 A | 22113 | 0 | 0 | $0 |
| Paul Herendeen | Exec. V.P. and CFO | 19 يوليو، 2016 A | · | 0 | 0 | $0 |
| Julie Fuller | Executive Vice President | 30 سبتمبر، 2026 M | 1588 | 0 | 0 | $0 |
| Kevin Esch | Executive Vice President | 10 يوليو، 2026 A | 578 | 0 | 0 | $0 |
| Keith Sarbaugh | Executive Vice President | 10 يوليو، 2026 A | 3346 | 0 | 0 | $0 |
| Rimma Driscoll | Executive Vice President | 10 يوليو، 2026 A | 5715 | 0 | 0 | $0 |
| Astorga Jeannette Ferran | Executive Vice President | 10 يوليو، 2026 A | 1684 | 0 | 0 | $0 |
| Abhay U Nayak | Executive Vice President | 10 يوليو، 2026 A | 1965 | 0 | 0 | $0 |
| Roxanne Lagano | Executive Vice President | 10 يوليو، 2026 A | 15632 | 0 | 0 | $0 |
| Jamie Brannan | Executive Vice President | 19 فبراير، 2026 M | 3290 | 0 | 0 | $0 |
| Nicholas Ashton | Executive Vice President | 19 فبراير، 2026 M | 1822 | 0 | 0 | $0 |
| Robert J Polzer | Executive Vice President | 10 أكتوبر، 2025 A | 5120 | 0 | 0 | $0 |
| Soria Ester Banque | Executive Vice President | 4 أكتوبر، 2024 A | 588 | 0 | 0 | $0 |
| Wafaa Mamilli | Executive Vice President | 4 أكتوبر، 2024 A | 6685 | 0 | 0 | $0 |
| Heidi C. Chen | Executive Vice President | 5 إبريل، 2024 A | 31293 | 0 | 0 | $0 |
| Glenn David | Executive Vice President | 13 يناير، 2023 A | 46572 | 0 | 0 | $0 |
| Timothy J Bettington | Executive Vice President | 7 أكتوبر، 2022 A | · | 0 | 0 | $0 |
| Roman Trawicki | Executive Vice President | 16 مارس، 2022 M | 8218 | 0 | 0 | $0 |
| Catherine A. Knupp | Executive Vice President | 10 نوفمبر، 2021 S | 43642 | 0 | 0 | $0 |
| Sherry N Pudloski | Executive Vice President | 8 أكتوبر، 2021 A | · | 0 | 0 | $0 |
| Robert Edward Kelly | Executive Vice President | 3 مايو، 2021 M | 8300 | 0 | 0 | $0 |
| James Michael Mcfarland | Executive Vice President | 9 إبريل، 2021 A | 2547 | 0 | 0 | $0 |
| Clinton A. Lewis Jr. | Executive Vice President | 16 ديسمبر، 2019 M | 27904 | 0 | 0 | $0 |
| Andrew Fenton | Executive Vice President | 6 ديسمبر، 2019 M | 23073 | 0 | 0 | $0 |
| Alejandro Bernal | Executive Vice President | 27 فبراير، 2018 M | 11417 | 0 | 0 | $0 |
| Sandra J. Beaty | Executive Vice President | 30 إبريل، 2015 A | 6721 | 0 | 0 | $0 |
| Joyce J. Lee | Executive Vice President | 9 إبريل، 2015 A | 3838 | 0 | 0 | $0 |
| Stefan Weiskopf | Executive Vice President | 27 فبراير، 2015 A | 3658 | 0 | 0 | $0 |
| Mark Stetter | مدير | 17 سبتمبر، 2026 A | 1572 | 0 | 0 | $0 |
| Frank A Damelio | مدير | 7 أغسطس، 2026 G | 14808 | 1 | 0 | $501344 |
| Michael B Mccallister | مدير | 10 يونيو، 2026 G | 0 | 1 | 0 | $233280 |
| Louise M Parent | مدير | 20 مايو، 2026 M | 28394 | 0 | 0 | $0 |
| Paul Bisaro | مدير | 13 مايو، 2026 P | 27862 | 1 | 0 | $151760 |
| Gregory Norden | مدير | 9 مارس، 2026 G | 0 | 0 | 0 | $0 |
| Vanessa Broadhurst | مدير | 19 فبراير، 2026 M | 3920 | 0 | 0 | $0 |
| Antoinette Renee Leatherberry | مدير | 19 فبراير، 2026 M | 5280 | 0 | 0 | $0 |
| Willie M Reed | مدير | 19 فبراير، 2026 M | 12864 | 0 | 0 | $0 |
| Gavin Hattersley | مدير | 19 فبراير، 2026 M | 3354 | 0 | 0 | $0 |
| Khosla Sanjay | مدير | 19 فبراير، 2026 A | 1892 | 0 | 0 | $0 |
| Stephanie Tilenius | مدير | 18 فبراير، 2026 A | · | 0 | 0 | $0 |
| Robert W Scully | مدير | 21 مايو، 2025 M | 21489 | 0 | 0 | $0 |
| Linda Rhodes | مدير | 21 مايو، 2024 M | 11192 | 0 | 0 | $0 |
| Juan Ramon Alaix | مدير | 20 مايو، 2021 D | 215129 | 0 | 0 | $0 |
| William C Steere JR | مدير | 20 مايو، 2021 M | 35074 | 0 | 0 | $0 |
| Charles H Hill | مدير | 6 فبراير، 2013 P | 5000 | 0 | 0 | $0 |
| Amy Schulman | مدير | 6 فبراير، 2013 P | 5000 | 0 | 0 | $0 |
| Douglas E. Giordano | مدير | 6 فبراير، 2013 P | 5000 | 0 | 0 | $0 |
| Geno J Germano | مدير | 6 فبراير، 2013 P | 5000 | 0 | 0 | $0 |
| Pfizer Inc. | مالك 10% | 24 يونيو، 2013 C | 0 | 0 | 0 | $0 |
| Richard A. Passov | · | 15 يوليو، 2014 A | 3706 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 154 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| IHE · iShares Trust | 3,78% | 840871 SH | 11 سبتمبر، 2026 | يومي |
| SMRI · EA Series Trust | 1,83% | 152486 NS | 31 يوليو، 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,82% | 246575 NS | 31 يوليو، 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,56% | 37663 SH | 1 أكتوبر، 2026 | يومي |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,56% | 194540 SH | 1 أكتوبر، 2026 | يومي |
| CVAR · ETF Opportunities Trust | 1,40% | 7761 NS | 31 يوليو، 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,08% | 2889 NS | 31 يوليو، 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,93% | 221136 SH | 1 أكتوبر، 2026 | يومي |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,74% | 17243 NS | 31 يوليو، 2026 | N-PORT |
| IWP · iShares Trust | 0,71% | 1867940 SH | 11 سبتمبر، 2026 | يومي |
| COWZ · Pacer Funds Trust | 0,62% | 1502929 NS | 31 يوليو، 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0,59% | 2890747 SH | 19 أغسطس، 2026 | يومي |
| FLAG · Global X Funds | 0,56% | 123 NS | 31 يوليو، 2026 | N-PORT |
| ESLV · Strategy Shares | 0,52% | 951 NS | 31 يوليو، 2026 | N-PORT |
| PABU · iShares Trust | 0,51% | 174679 SH | 11 سبتمبر، 2026 | يومي |
| IYH · iShares Trust | 0,49% | 246300 SH | 11 سبتمبر، 2026 | يومي |
| FHLC · FIDELITY COVINGTON TRUST | 0,47% | 200057 NS | 31 يوليو، 2026 | N-PORT |
| RCGE · EA Series Trust | 0,47% | 6141 NS | 31 يوليو، 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,45% | 1264118 SH | 19 أغسطس، 2026 | يومي |
| IXJ · iShares Trust | 0,39% | 219915 SH | 10 سبتمبر، 2026 | يومي |
| CURE · Direxion Shares ETF Trust | 0,37% | 8250 NS | 31 يوليو، 2026 | N-PORT |
| NULC · Nushares ETF Trust | 0,35% | 3218 NS | 31 يوليو، 2026 | N-PORT |
| ESUM · Strategy Shares | 0,33% | 7829 NS | 31 يوليو، 2026 | N-PORT |
| FQAL · FIDELITY COVINGTON TRUST | 0,31% | 57270 NS | 31 يوليو، 2026 | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,31% | 10926000 | 1 أكتوبر، 2026 | يومي |
| SUSA · iShares Trust | 0,30% | 164110 SH | 11 سبتمبر، 2026 | يومي |
| VFVA · VANGUARD WELLINGTON FUND | 0,29% | 33789 SH | 19 أغسطس، 2026 | يومي |
| SPHQ · Invesco Exchange-Traded Fund Trust | 0,28% | 754260 SH | 1 أكتوبر، 2026 | يومي |
| RECS · Columbia ETF Trust I | 0,28% | 212600 NS | 31 يوليو، 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,26% | 8177172 SH | 19 أغسطس، 2026 | يومي |
| EVUS · iShares Trust | 0,25% | 13282 SH | 11 سبتمبر، 2026 | يومي |
| IMCV · iShares Trust | 0,25% | 39931 SH | 11 سبتمبر، 2026 | يومي |
| DUHP · Dimensional ETF Trust | 0,24% | 375907 NS | 31 يوليو، 2026 | N-PORT |
| QDF · FlexShares Trust | 0,23% | 67413 NS | 31 يوليو، 2026 | N-PORT |
| IWR · iShares Trust | 0,23% | 1725551 SH | 11 سبتمبر، 2026 | يومي |
| IMCB · iShares Trust | 0,21% | 49261 SH | 11 سبتمبر، 2026 | يومي |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 2668324 SH | 1 أكتوبر، 2026 | يومي |
| JQUA · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 206683 NS | 31 يوليو، 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,19% | 50884 SH | 11 سبتمبر، 2026 | يومي |
| LRND · New York Life Investments ETF Trust | 0,18% | 9465 NS | 31 يوليو، 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,18% | 5589000 | 1 أكتوبر، 2026 | يومي |
| DGRO · iShares Trust | 0,18% | 1051645 SH | 11 سبتمبر، 2026 | يومي |
| IMCG · iShares Trust | 0,18% | 97153 SH | 11 سبتمبر، 2026 | يومي |
| SIZE · iShares Trust | 0,18% | 10276 SH | 11 سبتمبر، 2026 | يومي |
| XOEF · iShares Trust | 0,17% | 526 SH | 11 سبتمبر، 2026 | يومي |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,17% | 7877000 | 1 أكتوبر، 2026 | يومي |
| LCOW · Pacer Funds Trust | 0,16% | 529 NS | 31 يوليو، 2026 | N-PORT |
| CATH · Global X Funds | 0,15% | 25943 NS | 31 يوليو، 2026 | N-PORT |
| ESGU · iShares Trust | 0,15% | 364501 SH | 10 سبتمبر، 2026 | يومي |
| ESMV · iShares Trust | 0,15% | 158 SH | 10 سبتمبر، 2026 | يومي |
| GSY · Invesco Actively Managed Exchange-T… | 0,15% | 5769000 | 1 أكتوبر، 2026 | يومي |
| PALC · Pacer Funds Trust | 0,15% | 3973 NS | 31 يوليو، 2026 | N-PORT |
| QUAL · iShares Trust | 0,14% | 888569 SH | 11 سبتمبر، 2026 | يومي |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,13% | 175000 | 1 أكتوبر، 2026 | يومي |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,13% | 2368421 SH | 19 أغسطس، 2026 | يومي |
| VYM · VANGUARD WHITEHALL FUNDS | 0,13% | 1680027 SH | 19 أغسطس، 2026 | يومي |
| NUDV · Nushares ETF Trust | 0,13% | 834 NS | 31 يوليو، 2026 | N-PORT |
| USXF · iShares Trust | 0,12% | 24978 SH | 11 سبتمبر، 2026 | يومي |
| ESG · FlexShares Trust | 0,12% | 2010 NS | 31 يوليو، 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,12% | 6837 NS | 31 يوليو، 2026 | N-PORT |
| PFM · Invesco Exchange-Traded Fund Trust | 0,11% | 11940 SH | 1 أكتوبر، 2026 | يومي |
| IVE · iShares Trust | 0,10% | 695597 SH | 11 سبتمبر، 2026 | يومي |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,10% | 14060 SH | 1 أكتوبر، 2026 | يومي |
| IQSU · New York Life Investments ETF Trust | 0,10% | 4253 NS | 31 يوليو، 2026 | N-PORT |
| VTV · VANGUARD INDEX FUNDS | 0,10% | 3598101 SH | 19 أغسطس، 2026 | يومي |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,10% | 96479 SH | 19 أغسطس، 2026 | يومي |
| CHRI · Global X Funds | 0,10% | 102 NS | 31 يوليو، 2026 | N-PORT |
| LGDX · Tidal Trust III | 0,10% | 1814 NS | 31 يوليو، 2026 | N-PORT |
| IUSV · iShares Trust | 0,10% | 368059 SH | 11 سبتمبر، 2026 | يومي |
| REVS · Columbia ETF Trust I | 0,09% | 3986 NS | 31 يوليو، 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 10356 SH | 1 أكتوبر، 2026 | يومي |
| SUSL · iShares Trust | 0,09% | 14854 SH | 11 سبتمبر، 2026 | يومي |
| DSI · iShares Trust | 0,09% | 64531 SH | 11 سبتمبر، 2026 | يومي |
| HAPI · Harbor ETF Trust | 0,08% | 5320 NS | 31 يوليو، 2026 | N-PORT |
| AQLT · iShares Trust | 0,08% | 3693 SH | 10 سبتمبر، 2026 | يومي |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,08% | 55607 SH | 1 أكتوبر، 2026 | يومي |
| WRND · New York Life Investments ETF Trust | 0,08% | 109 NS | 31 يوليو، 2026 | N-PORT |
| MPLY · Strategy Shares | 0,08% | 158 NS | 31 يوليو، 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,08% | 5377 NS | 31 يوليو، 2026 | N-PORT |
| ESGG · FlexShares Trust | 0,07% | 1064 NS | 31 يوليو، 2026 | N-PORT |
| EGLE · Global X Funds | 0,07% | 21 NS | 31 يوليو، 2026 | N-PORT |
| IWF · iShares Trust | 0,07% | 1245265 SH | 11 سبتمبر، 2026 | يومي |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0,07% | 521663 SH | 19 أغسطس، 2026 | يومي |
| IWS · iShares Trust | 0,06% | 135157 SH | 11 سبتمبر، 2026 | يومي |
| PRF · Invesco Exchange-Traded Fund Trust | 0,06% | 85655 SH | 1 أكتوبر، 2026 | يومي |
| CRBN · iShares Trust | 0,06% | 9378 SH | 10 سبتمبر، 2026 | يومي |
| TOPC · iShares Trust | 0,06% | 258 SH | 11 سبتمبر، 2026 | يومي |
| ACVF · ETF Opportunities Trust | 0,06% | 1125 NS | 31 يوليو، 2026 | N-PORT |
| USCL · iShares Trust | 0,06% | 22073 SH | 10 سبتمبر، 2026 | يومي |
| HQGO · Lattice Strategies Trust | 0,06% | 354 NS | 31 يوليو، 2026 | N-PORT |
| XTR · Global X Funds | 0,05% | 34 NS | 31 يوليو، 2026 | N-PORT |
| XYLG · Global X Funds | 0,05% | 452 NS | 31 يوليو، 2026 | N-PORT |
| XRMI · Global X Funds | 0,05% | 344 NS | 31 يوليو، 2026 | N-PORT |
| XVV · iShares Trust | 0,05% | 4833 SH | 10 سبتمبر، 2026 | يومي |
| XCLR · Global X Funds | 0,05% | 24 NS | 31 يوليو، 2026 | N-PORT |
| ILCV · iShares Trust | 0,05% | 9460 SH | 11 سبتمبر، 2026 | يومي |
| PTLC · Pacer Funds Trust | 0,05% | 21352 NS | 31 يوليو، 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,05% | 57993 NS | 31 يوليو، 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,05% | 7112 NS | 31 يوليو، 2026 | N-PORT |
| XYLD · Global X Funds | 0,05% | 21020 NS | 31 يوليو، 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0,05% | 10888932 SH | 19 أغسطس، 2026 | يومي |
| ESGV · VANGUARD WORLD FUND | 0,05% | 95134 SH | 19 أغسطس، 2026 | يومي |
| TOV · EA Series Trust | 0,05% | 1758 NS | 31 يوليو، 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0,05% | 34718 NS | 31 يوليو، 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0,05% | 36 NS | 31 يوليو، 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,05% | 64727 SH | 1 أكتوبر، 2026 | يومي |
| IVV · iShares Trust | 0,05% | 5283923 SH | 11 سبتمبر، 2026 | يومي |
| ILCB · iShares Trust | 0,05% | 8221 SH | 9 سبتمبر، 2026 | يومي |
| SPUU · Direxion Shares ETF Trust | 0,05% | 1582 NS | 31 يوليو، 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,05% | 10102 NS | 31 يوليو، 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,04% | 72430 SH | 1 أكتوبر، 2026 | يومي |
| PBP · Invesco Exchange-Traded Fund Trust | 0,04% | 2457 SH | 1 أكتوبر، 2026 | يومي |
| DFAU · Dimensional ETF Trust | 0,04% | 70832 NS | 31 يوليو، 2026 | N-PORT |
| IYY · iShares Trust | 0,04% | 18056 SH | 10 سبتمبر، 2026 | يومي |
| IWB · iShares Trust | 0,04% | 290521 SH | 11 سبتمبر، 2026 | يومي |
| IWV · iShares Trust | 0,04% | 115640 SH | 10 سبتمبر، 2026 | يومي |
| ITOT · iShares Trust | 0,04% | 544118 SH | 11 سبتمبر، 2026 | يومي |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,04% | 9771 SH | 1 أكتوبر، 2026 | يومي |
| ILCG · iShares Trust | 0,04% | 17162 SH | 11 سبتمبر، 2026 | يومي |
| VV · VANGUARD INDEX FUNDS | 0,04% | 440643 SH | 19 أغسطس، 2026 | يومي |
| VTI · VANGUARD INDEX FUNDS | 0,04% | 11984400 SH | 19 أغسطس، 2026 | يومي |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,04% | 69366 SH | 19 أغسطس، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,04% | 35465 SH | 19 أغسطس، 2026 | يومي |
| HCMT · Direxion Shares ETF Trust | 0,04% | 2917 NS | 31 يوليو، 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,04% | 17007 NS | 31 يوليو، 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,04% | 32772 NS | 31 يوليو، 2026 | N-PORT |
| TOK · iShares Trust | 0,04% | 1209 SH | 11 سبتمبر، 2026 | يومي |
| PHDG · Invesco Actively Managed Exchange-T… | 0,04% | 325 SH | 1 أكتوبر، 2026 | يومي |
| URTH · iShares, Inc. | 0,03% | 37976 SH | 10 سبتمبر، 2026 | يومي |
| DFSU · Dimensional ETF Trust | 0,03% | 9950 NS | 31 يوليو، 2026 | N-PORT |
| ACWI · iShares Trust | 0,03% | 138514 SH | 9 سبتمبر، 2026 | يومي |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,03% | 356907 SH | 19 أغسطس، 2026 | يومي |
| TILT · FlexShares Trust | 0,03% | 8216 NS | 31 يوليو، 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,03% | 69465 NS | 31 يوليو، 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,02% | 2228 NS | 31 يوليو، 2026 | N-PORT |
| NULV · Nushares ETF Trust | 0,02% | 5737 NS | 31 يوليو، 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 54015 SH | 19 أغسطس، 2026 | يومي |
| IWD · iShares Trust | 0,02% | 198738 SH | 11 سبتمبر، 2026 | يومي |
| QDEF · FlexShares Trust | 0,02% | 1148 NS | 31 يوليو، 2026 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0,00% | 3000 | 30 سبتمبر، 2026 | يومي |
| GTO · Invesco Actively Managed Exchange-T… | 0,00% | 66000 | 1 أكتوبر، 2026 | يومي |
| DFAC · Dimensional ETF Trust | 0,00% | 6792 NS | 31 يوليو، 2026 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 يوليو، 2026 | يومي |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 يوليو، 2026 | يومي |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 يوليو، 2026 | يومي |
| VCEB · VANGUARD WORLD FUND | · | · | 30 يوليو، 2026 | يومي |
ZTS توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
تصنيف · 24 محللين
شراء
السعر المستهدف الوسيط
$89.50
+28,4%
4 16,7%
شراء قوي
8 33,3%
شراء
12 50,0%
احتفاظ
0 0,0%
بيع
0 0,0%
بيع قوي
السعر المستهدف لمدة 12 شهرًا
14 محللين · 2026-09-28السعر المستهدف المتوسط $96.00 +37,8%
← أقل من جميع الأهداف
السعر الحالي $69.69
منخفض$80.00
المتوسط$96.00
مرتفع$155.00
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
أساس السنة المالية، الأسعار كما في إغلاق نهاية السنة المالية الأخيرة لكل شركة.
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | · |
| JNJ | · | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | · | 14.5 | 1.3% | 28.1% | 36.9% | · |
| PFE | · | 18.3 | -1.7% | 12.4% | 8.9% | · |
| BMY | · | 15.6 | -0.22% | 14.6% | 40.5% | · |
| RPRX | · | 21.7 | 5.1% | 32.4% | 8.0% | · |
| VTRS | · | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | · |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة + بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
المصدر: إيداع SEC 10-Q بتاريخ أغسطس 6, 2026